SINGAPORE - 9 February 2026 - Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has acquired all rights, title, and interest in and to the Zam-Buk and Vapex consumer healthcare brands from Bayer Consumer Care AG for Thailand, Singapore, Indonesia, Malaysia and Brunei.

Zam-Buk is an ointment used for the temporary relief of pain and itch, including discomfort from insect bites. First launched in 1902, Zam-Buk has retained strong brand equity over the decades and is widely perceived as a trusted household brand. Vapex is a nasal inhaler used to help relieve nasal congestion. Launched in 1917, Vapex has built meaningful brand recognition, particularly in Thailand.

The acquisition of the brands supports Zuellig Pharma's strategic priority to strengthen and scale its consumer healthcare portfolio across Asia. It also marks the company's second consumer healthcare acquisition, following Propan in the Philippines, reinforcing its focus on building a strong commercial platform for trusted, everyday healthcare products in the region.

"This acquisition marks another significant growth milestone for our consumer healthcare product portfolio. Zam-Buk and Vapex are enduring brands with deep heritage and trust in the communities they serve. By combining the brands' legacy with Zuellig Pharma's regional commercial capabilities and local market expertise, we aim to expand distribution and access across all relevant retail channels in the region. In doing so, these brands will continue to remain relevant, easy to find, and accessible to consumers." said John Graham, CEO of Zuellig Pharma.

Hashtag: #ZuelligPharma  #ConsumerHealthcare  #ConsumerHealth  #Healthcare  #Pharmaceuticals  #Zambuk  #Vapex  #Bayer 

The issuer is solely responsible for the content of this announcement.